Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2019 | Managing CRS in CAR T-cell therapy

Miguel-Angel Perales • 5 Apr 2019
EBMT 2019
Leukemia Lymphoma Multiple Myeloma

Miguel-Angel Perales, MD, of Memorial Sloan Kettering Cancer Center, New York, NY, examines the importance of practical management of patients in treatment of cytokine release syndrome (CRS). Dr Perales was speaking at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.

More from Miguel-Angel Perales

2:53
The utility of CD34-selected peripheral blood stem cell graft as GvHD prevention in HLA allografts
Miguel-Angel Perales • 28 Oct 2022
1:53
Prolymphocytes as a promising GvHD prophylaxis
Miguel-Angel Perales • 28 Oct 2022
1:42
Transplantation and cell therapy highlights at COSTEM 2022
Miguel-Angel Perales • 28 Oct 2022
1:17
The impact of CAR-T therapy in the second-line setting in lymphoma
Miguel-Angel Perales • 28 Oct 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals